## Klemens Hoegenauer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1084441/publications.pdf

Version: 2024-02-01

		1162367	1473754
10	303	8	9
papers	citations	h-index	g-index
10	10	10	467
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 975-980.	1.3	70
2	Structural States of RORγt: Xâ€ray Elucidation of Molecular Mechanisms and Binding Interactions for Natural and Synthetic Compounds. ChemMedChem, 2017, 12, 1014-1021.	1.6	56
3	Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 762-767.	1.3	50
4	Retinoic-acid-orphan-receptor-C inhibition suppresses Th 17 cells and induces thymic aberrations. JCI Insight, 2017, 2, e91127.	2.3	46
5	Synthesis of Chiral Analoguesof FTY720 and its Phosphate. Synthesis, 2003, 2003, 1667-1670.	1.2	22
6	Optimizing a Weakly Binding Fragment into a Potent ROR $\hat{I}^3$ t Inverse Agonist with Efficacy in an in Vivo Inflammation Model. Journal of Medicinal Chemistry, 2018, 61, 6724-6735.	2.9	22
7	Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5657-5662.	1.0	18
8	Structure-Based and Property-Driven Optimization of $\langle i \rangle N \langle  i \rangle$ -Aryl Imidazoles toward Potent and Selective Oral RORÎ <sup>3</sup> t Inhibitors. Journal of Medicinal Chemistry, 2019, 62, 10816-10832.	2.9	15
9	On the reactivity of ascomycin at the binding domain. Part 3: Reactivity of the binding domain towards diazomethane. Tetrahedron, 2005, 61, 4819-4829.	1.0	4
10	The 2 nd Alpine Winter Conference on Medicinal and Synthetic Chemistry. ChemMedChem, 2021, 16, 2417-2423.	1.6	O